Pharmaspire
× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Submit Article Author Guidelines Advertise Join as Reviewer Contact Editorial Policies and Peer Review Process Journal Policies Publishing Ethics


 

Original Article
Year : 2020   |  Volume : 12  |  Issue : 3  |  Page : 104-107

Efficacy of montelukast when added with inhaled corticosteroids on mild-to-moderate asthmatic patients

Objective: Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. Methods: A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Results: Patients were randomized into two groups viz., control group(n=59) and the treatment group(n=59).Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day along with Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant difference was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%).Even though 12% FEV1 improvement were observed, the rate of improvement was not significant (p>0.5).There is no serious adverse drug reaction among the tested groups. Conclusion: The study concluded that addition of Montelukast 10 mg to the inhaled Budesonide is an effective and alternative treatment option to doubling the dose of inhaled Budesonide.
[]*
Print this article     Email this article